DPP-4 Inhibitors in the Prevention/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19—A Therapeutic Approach of Choice in Type 2 Diabetic Patients?

Overview of attention for article published in Frontiers in Pharmacology, August 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter: 2 X users

Citations

dimensions_citation: 21 Dimensions

Readers on

mendeley: 77 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 21 publications that cite this research output.

21

The most recent citing publications are shown below. View all 21 publications that cite this research output on Dimensions.

Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis

Article in World Journal of Clinical Cases (February 2024)

The Effects of Dipeptidyl Peptidase-4 Inhibitors on Kidney Function in Advanced CKD

Article in JOURNAL OF BIOTECHNOLOGY AND STRATEGIC HEALTH RESEARCH (October 2023)

Bioinformatics and next generation data analysis reveals the potential role of inflammation in sepsis and its associated complications

Preprint in bioRxiv (August 2023)